MedPath

Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Ropeginterferon Alfa-2b Evaluated in Phase III Trial for Essential Thrombocythemia

• The ROP-ET trial is a phase III study assessing ropeginterferon alfa-2b for essential thrombocythemia (ET) patients ineligible for or resistant/intolerant to other cytoreductive treatments. • The primary objective is to determine the disease response rate at 12 months, based on modified ELN criteria, including blood count remission and symptom improvement. • Secondary endpoints include assessing long-term efficacy, disease modification (JAK2, CALR, MPL allele burden), safety, and quality of life over 36 months. • The study aims to enroll 117 patients to ensure 93 are evaluable, with interim analysis planned after all patients reach the 12-month mark.
© Copyright 2025. All Rights Reserved by MedPath